Kidney Damage in Patients With Moderate Fall in eGFR

Completed · Phase 4

Conditions studied: Coronary Artery Stenosis

In brief

To compare Iopamidol injection 370 and Iodixanol 320 in evaluating Neutrophil Gelatinase-Associated Lipocalin (NGAL) in patients with moderate fall in eGFR

Key facts

Study ID

NCT01136876

Run by

Bracco Diagnostics, Inc

People needed

57

Starts

2010-11-01

Expected to finish

2012-11-01

Last updated by the study team

2020-11-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least 18 years of age and provides informed consent
• Scheduled to undergo percutaneous coronary intervention
• Documented pre-dose Estimated glomerular filtration rate (eGFR) of greater than or equal to 30 mL/min/1.73 m squared and less than or equal to 59 mL/min/1.73 m squared

You may not qualify if…

• Pregnant or lactating females
• Severe congestive heart failure
• History of hyperthyroidism;
• Unstable renal function
• Emergency PCI
• History of hypersensitivity to iodinated contrast agents
• Receiving diuretics to prevent acute renal injury

Where it is running

• Research Cooperative, St. John's Hospital — Springfield, Illinois, United States
• UMDNJ - RWJ Medical School — New Brunswick, New Jersey, United States
• The Institute for Clinical Research at Holy Name Medical Center — Teaneck, New Jersey, United States
• Montreal Heart Institute — Montreal, Quebec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.